MK2 regulates the early stages of skin tumor promotion

Carcinogenesis

Volumn 30, Issue 12, 2009, Pages 2100-2108

  Johansen, Claus ^a   Vestergaard, Christian ^a   Kragballe, Knud ^a   Kollias, George ^b   Gaestel, Matthias ^c   Iversen, Lars ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MYELOPEROXIDASE; PHORBOL 12 ACETATE 13 MYRISTATE; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA; MAP KINASE ACTIVATED KINASE 2; MAP-KINASE-ACTIVATED KINASE 2; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL COUNT; CONTROLLED STUDY; EPIDERMIS CELL; FEMALE; GENE EXPRESSION; KERATINOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SKIN TUMOR; TUMOR SUPPRESSOR GENE; ANIMAL; DISEASE COURSE; DNA DAMAGE; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; APOPTOSIS; DISEASE PROGRESSION; DNA DAMAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; INFLAMMATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KERATINOCYTES; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING; SKIN NEOPLASMS; TETRADECANOYLPHORBOL ACETATE; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 73949120882     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp238     Document Type: Article

References (39)

1. Rouse,J. et al. (2002) Interfaces between the detection, signaling, and repair of DNA damage. Science, 297, 547-551.
2. Yuspa,S.H. (1994) The pathogenesis of squamous cell cancer: lessons learned from studies of skin carcinogenesis-thirty-third G.H.A. Clowes Memorial Award Lecture. Cancer Res., 54, 1178-1189.
3. Coussens,L.M. et al. (2002) Inflammation and cancer. Nature, 420, 860-867.
4. de Visser,K.E. et al. (2006) Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer, 6, 24-37.
5. Fox,J.G. et al. (2007) Inflammation, atrophy, and gastric cancer. J. Clin. Invest., 117, 60-69.
6. Balkwill,F. et al. (2001) Inflammation and cancer: back to Virchow? Lancet, 357, 539-545.
7. Lin,W.W. et al. (2007) A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest., 117, 1175-1183.
8. Karin,M. et al. (2006) Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell, 124, 823-835.
9. Palapattu,G.S. et al. (2005) Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis, 26, 1170-1181.
10. Balkwill,F. (2002) Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev., 13, 135-141.
11. Moore,R.J. et al. (1999) Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat. Med., 5, 828-831.
12. Gaestel,M. (2006) MAPKAP kinases-MKs-two's company, three's a crowd. Nat. Rev. Mol. Cell Biol., 7, 120-130.
13. Johansen,C. et al. (2006) Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J. Immunol., 176, 1431-1438.
14. Kotlyarov,A. et al. (1999) MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat. Cell Biol., 1, 94-97.
15. Neininger,A. et al. (2002) MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels. J. Biol. Chem., 277, 3065-3068.
16. Winzen,R. et al. (1999) The p38 MAP kinase pathway signals for cytokineinduced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J., 18, 4969-4980.
17. Harms,K. et al. (2004) The common and distinct target genes of the p53 family transcription factors. Cell. Mol. Life Sci., 61, 822-842.
18. Green,D.R. et al. (2006) p53 and metabolism: inside the TIGAR. Cell, 126, 30-32.
19. Freedman,D.A. et al. (1999) Regulation of the p53 protein by the MDM2 oncoprotein-thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res., 59, 1-7.
20. Jones,S.N. et al. (1995) Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature, 378, 206-208.
21. Montes de Oca Luna, R. et al. (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature, 378, 203-206.
22. Ma,L. et al. (2005) A plausible model for the digital response of p53 to DNA damage. Proc. Natl Acad. Sci. USA, 102, 14266-14271.
23. Alarcon-Vargas,D. et al. (2002) p53-Mdm2-the affair that never ends. Carcinogenesis, 23, 541-547.
24. Haupt,Y. et al. (1997) Mdm2 promotes the rapid degradation of p53. Nature, 387, 296-299.
25. Honda,R. et al. (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett., 420, 25-27.
26. Kubbutat,M.H. et al. (1997) Regulation of p53 stability by Mdm2. Nature, 387, 299-303.
27. Weber,H.O. et al. (2005) HDM2 phosphorylation by MAPKAP kinase 2. Oncogene, 24, 1965-1972.
28. Pasparakis,M. et al. (1996) Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J. Exp. Med., 184, 1397-1411.
29. Ananieva,O. et al. (2008) The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling. Nat. Immunol., 9, 1028-1036.
30. Scott,K.A. et al. (2003) An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors. Mol. Cancer Ther., 2, 445-451.
31. Acarturk,T.O. et al. (2005) Nonmelanoma skin cancer. Clin. Plast. Surg., 32, 237-248.
32. Arnott,C.H. et al. (2004) Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. Oncogene, 23, 1902-1910.
33. Hitti,E. et al. (2006) Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element. Mol. Cell. Biol., 26, 2399-2407.
34. Riley,T. et al. (2008) Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol., 9, 402-412.
35. Vousden,K.H. et al. (2002) Live or let die: the cell's response to p53. Nat. Rev. Cancer, 2, 594-604.
36. Norimura,T. et al. (1996) p53-dependent apoptosis suppresses radiationinduced teratogenesis. Nat. Med., 2, 577-580.
37. Brooks,C.L. et al. (2006) p53 ubiquitination: mdm2 and beyond. Mol. Cell., 21, 307-315.
38. Ringshausen,I. et al. (2006) Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell, 10, 501-514.
39. Reinhardt,H.C. et al. (2007) p53-deficient cells rely on ATM-and ATRmediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell, 11, 175-189.